OBJECTIVES: The FIRE study describes the real-life experience of patients with endometrial cancer (EC), including disease characteristics, treatments, outcomes and HCRU. This abstract focuses on HCRU and associated medical costs.

METHODS: FIRE is a multicentre, retrospective, non-interventional chart review of records from 2014–2022 in Helsinki, Turku and Tampere University Hospitals. Data were collected for patients diagnosed with incident recurrent or advanced EC receiving first-line platinum- and taxane-based treatments in these hospitals, which cover ~50% of the total Finnish EC population.

RESULTS: This study identified 266 patients, among whom 213 (80.1%) had Stage III and 53 (19.9%) had Stage IV initial diagnoses. In addition, tumours of 19 patients had deficient mismatch repair status (dMMR), while 43 were MMR proficient (MMRp) and 204 were MMR unknown. During the first treatment year, there was an average of 29.7 EC-related outpatient visits per patient (MMRp: 36.5; dMMR: 30.9), 11.9 radiotherapy contacts (MMRp: 10.2; dMMR: 12.3) and 0.9 hospitalisations (MMRp: 0.5; dMMR: 1.3), with an average hospitalisation stay of 3 days (MMRp: 1.8; dMMR: 5.5). Average total cost of outpatient visits per patient was €10,890 (MMRp: €13,036; dMMR: €11,130) and average radiotherapy treatment cost was €4482 (MMRp: €3918;.dMMR: €4776). Costs decreased to €2428 in the second treatment year (MMRp: €3018; dMMR: €1790) for outpatient visits and to €919 for radiotherapy contacts (MMRp: €1115; dMMR: €683).

CONCLUSIONS: EC-related HCRU and healthcare costs are higher in the first year after diagnosis. Varied HCRU and costs were seen between MMR groups; however, MMR status was mostly unknown. These results further suggest the importance of MMR testing.